Director-affiliated fund sells $127.4M in Cogent Biosciences stock
summarizeZusammenfassung
Fairmount Funds Management LLC, an entity affiliated with a director, executed a substantial open market sale of Cogent Biosciences stock totaling $127.4 million. This significant disposition, representing over 2% of the company's market capitalization, could signal a reduction in conviction from a key institutional investor and director-affiliated entity. The shares were sold at $36.40, below the current market price of $39.53. Investors should monitor for further insider activity or any related company announcements.
check_boxSchlusselereignisse
-
Significant Insider Sale
Fairmount Funds Management LLC, an entity affiliated with a director, sold 3,500,000 shares of Cogent Biosciences common stock for a total value of $127,400,000.
-
Substantial Stake Reduction
The sale represents a significant portion of the company's market capitalization and reduces the reporting owner's common stock holdings to 5,503,418 shares post-transaction.
-
Transaction Details
The shares were sold at a price of $36.40 per share on January 22, 2026, which is below the current stock price of $39.53.
auto_awesomeAnalyse
Fairmount Funds Management LLC, an entity affiliated with a director, executed a substantial open market sale of Cogent Biosciences stock totaling $127.4 million. This significant disposition, representing over 2% of the company's market capitalization, could signal a reduction in conviction from a key institutional investor and director-affiliated entity. The shares were sold at $36.40, below the current market price of $39.53. Investors should monitor for further insider activity or any related company announcements.
Zum Zeitpunkt dieser Einreichung wurde COGT bei 39,53 $ gehandelt an der NASDAQ im Sektor Life Sciences, bei einer Marktkapitalisierung von rund 6 Mrd. $. Die 52-Wochen-Handelsspanne lag zwischen 3,72 $ und 43,73 $. Diese Einreichung wurde mit negativer Marktstimmung und einem Wichtigkeitsscore von 9 von 10 bewertet.